04.14.11
Roche 1Q
1Q Revenues: $12.4 billion (-9%)
Comments: Pharmaceuticals Division sales were down 2% in the quarter. Avastin sales were impacted by regulatory and reimbursement uncertainty in the U.S. for the metastatic breast cancer indication. Lucentis, MabThera/Rituxan, Herceptin, Actemra/RoActemra, Activase/TNKase, Tarceva and Xeloda, performed well in the quarter. The exchange rate impacted sales by 1.1 billion Swiss francs or 9%.
1Q Revenues: $12.4 billion (-9%)
Comments: Pharmaceuticals Division sales were down 2% in the quarter. Avastin sales were impacted by regulatory and reimbursement uncertainty in the U.S. for the metastatic breast cancer indication. Lucentis, MabThera/Rituxan, Herceptin, Actemra/RoActemra, Activase/TNKase, Tarceva and Xeloda, performed well in the quarter. The exchange rate impacted sales by 1.1 billion Swiss francs or 9%.